Tuesday, September 29
Gene therapy hope collapses as drug data disappoints badly
A closely watched Huntington's disease treatment showed its benefits fading over time, sending its maker's stock into freefall and raising hard questions about the entire program.
Top Stories
uniQure's Huntington's drug is losing its punch just when it needs to prove itself
uniQure shares cratered more than a third on Tuesday after new data showed that the disease-slowing benefit from its high-dose gene therapy had shrunk from 75% at the three-year mark to just 44% at four years, and the result no longer cleared the statistical bar that scientists use to distinguish a real effect from noise.
The company insists it can still win regulatory approval by leaning on the stronger earlier data, but a drug that appears to wear off over time faces a fundamentally harder sell to regulators who want to see treatments hold up, not fade.
Apple's leadership overhaul signals the Tim Cook era's engineering culture is being dismantled
New Apple chief executive John Ternus unveiled a sweeping reorganization Tuesday designed to flatten the company's structure, speed up product development, and push decision-making closer to engineers, a sharp departure from the management style that defined the Cook years.
The market's roughly 2% negative reaction suggests investors read the shake-up less as a confident reset and more as an admission that Apple's current structure has been slowing it down at exactly the moment rivals are moving faster on artificial intelligence.
Netflix's upgrade is a bet that Wall Street has been punishing the wrong company
Deutsche Bank flipped its rating on Netflix to a buy on Tuesday, arguing that a 25% year-to-date slide has made the stock cheap relative to an asset most rivals simply cannot replicate: a global production network that lets Netflix make content everywhere at once.
The call is a direct challenge to the prevailing narrative that softening U.S. viewership is a structural problem, suggesting instead that the selloff has been driven by short-term noise rather than any real crack in the company's long-term position.
Also Today
- Nvidia's $235 billion buyback signals confidence in its own cheap valuation
- Tesla secures $30 billion in funding, but Cybercab timeline slips to 2027
- Meta rebounds as Zuckerberg takes Muse to small businesses and the White House
Takeaway
The day's biggest story was not a giant company's earnings or a Fed decision but a single clinical data readout that erased a third of a small biotech's value and cast doubt on whether gene therapy's promise can survive long enough to matter.
Watch Apple over the next few sessions to see whether institutional investors treat the restructuring as a buying opportunity or a signal that the company has lost its operational identity.
